The biosimilar developer, which has closed a funding round led by Livzon Mabpharm, will take a majority share in the merged entity.
US-based pharmaceutical company Epirus Biopharmaceuticals announced today that it has completed $36m in a series B round led by biotechnology company Livzon Mabpharm and has agreed a merger deal with biopharmaceutical drug developer Zalicus.
Adage Capital, Greenwoods Investment, Gibralt, Monashee Capital Partners and an investment affiliate of Mousse Partners participated as new investors, while existing backers TPG Biotech, Montreux Equity Partners and 5AM Ventures were also involved.
Online deals database Crunchbase states that Epirus had raised about $13m in funding…
